Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haematitum (代赭石, Dai Zhe Shi) is a mineral-based traditional Chinese medicine primarily composed of ferric oxide (Fe2O3). It is officially listed in the Chinese Pharmacopoeia and is traditionally used to "subdue liver yang," "direct qi downward," and "stop bleeding." Clinically, it is employed to treat conditions such as belching, vomiting, hiccups, asthma, and various types of hemorrhage. While effective, it is considered slightly toxic and is often processed by calcination (calcined Haematitum) to reduce toxicity and improve friability for decoction. Recent studies have explored its potential for multi-organ toxicity (particularly pulmonary) at high doses and its role in complex TCM formulas like Xuanfu Daizhe Decoction for gastrointestinal disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haematitum.